Lediga tjänster Bli en del av Novartis, här kan du se mer om vilka karriärmöjligheter som finns.

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

First to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and Texas ...

Explore opportunities with Novartis below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these treatments to as many ...

A side effect is any unwanted medical occurrence in a patient who has been given a pharmaceutical product that may or may not have been caused by treatment with the product. By reporting side effects ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...

FDA approval based on robust Phase III data in which Cosentyx ® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor ...

V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni skupnosti strokovnjakov in našli ...

The Novartis Board of Directors is responsible for the direction, strategy, organization and administration of the company. The Board comprises 12 members with Giovanni Caforio as chair. Download the ...